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osting by EAbstract Retinoblastoma is one of the most important childhood tumors with genetic implications
and necessity for family counseling and long term follow up. We are presenting a 22 year-old Saudi
male with history of bilateral retinoblastoma, who was initially treated by enucleation of his left eye.
The histopathology showed a moderately differentiated tumor with vitreous seeding and he received
chemotherapy in addition to radiotherapy to his right eye. He presented 20 years later with a right
orbital tumor, frozen globe and proptosis. The excisional biopsy of his orbital mass revealed a spin-
dle cell sarcoma with features of malignant ﬁbrous histiocytoma. His clinical and radiological ﬁnd-
ings are presented together with the histopathologic features of his orbital tumor and brief review of
secondary tumors in retinoblastoma patients.
ª 2009 King Saud University. All rights reserved.1. Introduction
Retinoblastoma is one of the most common childhood malig-
nancies. It is responsible for approximately 1% of all deaths
from cancer in the paediatric age group (Apple and Rabb,
1998). Greater number of survivors of this tumor is recentlyology and Laboratory Medi-
ialist Hospital, P.O. Box 7191,
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lseviernoted due to the improved cure rates, thus there is an expected
increasing incidence of the retinoblastoma-inducing gene
throughout the general population (Apple and Rabb, 1998).
The incidence of other primary malignancies in hereditary ret-
inoblastoma survivors is estimated to be between 4% and 25%
at 10–30 years, respectively (Rozans, 2005).
With the advancing methods in the treatment of retinoblas-
toma by chemotherapy, the risk for secondary neoplasm is ex-
pected to be decreased in such patients, compared with cases
treated by primary enucleation and radiation (Rozans, 2005).
We have encountered a case of malignant orbital tumor in
one of our patients with bilateral retinoblastoma and history
of radiotherapy.
2. Case report
A 22-year-old Saudi male presented initially during his infancy
with bilateral retinoblastoma for which enucleation of his left
Figure 3 Another tumor area with large vacuolated cells
(Hematoxylin and Eosin · 400).
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enucleated globe revealed a multifocal moderately differenti-
ated retinoblastoma with signiﬁcant vitreous seeding, but no
optic nerve invasion or extrascleral extension. His bone mar-
row biopsy and CSF cytology were negative at that time. His
follow up post chemotherapy and external beam radiotherapy
to the right eye revealed slightly regressed tumor in that eye
and enucleation was advised. The patient was then lost to fol-
low up for 20 years.
He presented again with right side proptosis. The right
globe showed congested and chemotic conjunctiva with cor-
neal scarring and no further details of the posterior cavity.
The Magnetic Resonance Imaging (MRI) revealed large heter-
ogenous soft tissue mass in the right orbital cavity extending to
the orbital apex. Another tumor mass with calciﬁcation was
observed within the globe (Fig. 1). The orbital biopsy showed
diffuse abnormal proliferation of variable cells with high de-
gree of pleomorphism, large nuclei and prominent nucleoli.
Some of the proliferating cells are spindle in shape with stori-
form pattern (Fig. 2). Other cells are large, vacuolated with
slightly foamy cytoplasm (Fig. 3). These anaplastic cells have
a sworling arrangement in a ﬁne collagen matrix and they inﬁl-
trate the adipose tissue and the skeletal muscle ﬁbers present
with frequent abnormal mitotic ﬁgures. The tumor cells were
vimentin positive (Fig. 4) and show focal positivity with
CD68. The epithelial markers were negative supporting theFigure 1 Magnetic Resonance Imaging showing right orbital
tumor and the residual right intraocular mass.
Figure 2 Histopathologic appearance of the tumor cells with
storiform pattern (Hematoxylin and Eosin · 25).
Figure 4 Positive tumor cells with Vimentin Stain (·400).diagnosis of a sarcoma. Other negative stains include: S100,
HMB-45, Desmin, Myogenin, Muscle Speciﬁc Actin, and
CD34. The ﬁnal diagnosis was: malignant ﬁbrous histiocytoma
(MFH) of the right orbit.
3. Discussion
Fibrous histiocytomas are mesenchymal tumors that involve
soft tissues being the most common adult mesenchymal tumor
of the orbit (Rootman, 2003). It was ﬁrst described in 1960 and
the orbit was then identiﬁed as site of predilection by Zimmer-
man in 1967.
The neoplasm is characterized by inﬁltrative features, ten-
dency for local recurrence, rare metastasis and a biological
behavior which parallels the histopathologic features. The be-
nign type is the most common. The intermediate type has in-
creased cellularity and few mitotic ﬁgures. The least frequent
is the malignant type which can arise ‘‘de novo’’ or following
orbital radiotherapy. Rootman (2003) encountered three cases
of orbital malignant ﬁbrous histiocytoma (MFH) in his series
and one of these developed in the orbit of a child with history
of retinoblastoma. Shields et al. (2001) reviewed major reports
of second cancer after radiation for retinoblastoma and found
three ﬁbrous histiocytomas among 112 secondary tumors
Figure 5 The histopathologic appearance of the metastatic
lesion of the femoral neck (Hematoxylin and Eosin · 400).
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reported a case of (MFH) with conﬁrmation of the diagnosis
by histopathology, immunohistochemical and ultrastructural
ﬁndings.
Other reported secondary tumors (Font and Hidayat, 1982;
Dally, 1999; Font et al., 1983; Abramson et al., 1984; Roarty
et al., 1988; Sagerman et al., 1969; Abramson and Frank,
1998; Schlienger et al., 1985; Charis et al., 1993; Fontanesi
et al., 1995; Traboulsi et al., 1988) include osteogenic sarcoma
as the most common secondary tumor with 500 times higher
prevalence in such patients than in general population. Less
frequent tumors are ﬁbrosarcoma, leiomyosarcoma, rhabdo-
myosarcoma, and cutaneous tumors including malignant mel-
anoma, squamous cell carcinoma, sebaceous carcinoma and
basal cell carcinoma.
Radiologically it is difﬁcult to distinguish (MFH) from
other orbital masses. In these cases, the enhancement pattern
on Computed Tomography (CT) or MRI may be inhomoge-
neous with avascular or necrotic non-enhancing regions
(Dally, 1999).
The pathogenesis of secondary tumors in survivors of reti-
noblastoma has been extensively studied and the classical con-
cept of ‘‘radiocancer’’ is generally admitted with variable latent
period for the appearance of the common secondary tumors
ranging between 14.3 and 11 years for osteogenic sarcoma,
and between 16 and 12 years for other soft tissue sarcoma as
studied by Font et al. (1983). Abramson also concluded a
10.4 years mean latent period of second tumors in retinoblas-
toma survivors which favors radiation inducement as an etiol-
ogy in the pathogenesis of such tumors (Abramson et al.,
1984). The other factor which supports this relation is the
30 years cumulative incidence of second neoplasm in bilateral
retinoblastoma reported by Roarty et al. (1988) to be 35.1%
in patients who received radiation, compared to 5.8% in pa-
tients who did not receive radiation. Second tumors rate was
also found to be 29.3% within the ﬁeld of radiation and only
8.1% outside the ﬁeld.
In regard to the dose of radiation, Sagerman et al. (1969)
demonstrated a dose–response curve for incidence of second
tumors in relation to the radiation dose. On the other hand
Abramson et al. (1984) failed to demonstrate a relationship be-
tween the incidence and the dose of therapeutic radiation.
Then Zimmerman (Roarty et al., 1988) commented that the
higher risk in these survivors can be attributed to the old meth-
ods and the excessive doses of radiation used for treatment at
that time. Abramson further considered the age at the time of
radiation as an important factor and concluded that irradia-
tion before the age of 12 months is a risk factor (Abramson
and Frank, 1998). However, the fact that some of these tumors
develop in a different location from the irradiated area deﬁ-
nitely raises the possibility of other predisposing factors, most
importantly the genetic factor (Schlienger et al., 1985).
The prognosis in general shows a cumulative probability of
death from second neoplasm of 26% at 40 years after bilateral
retinoblastoma (Charis et al., 1993). Unfortunately MFH are
generally high grade sarcomas with tendency for local recur-
rence and possible distant metastasis (Dally, 1999).
This was evident in our patient where his systemic work-up
and bone scan revealed a metastatic lesion in the neck of the
left femur. The histopathology of the biopsy revealed an undif-
ferentiated sarcoma considered to be metastatic from his orbi-
tal lesion rather than being an osteogenic sarcoma (Fig. 5). Hereceived radiotherapy with poor response and the disease pro-
gressed with metastatic lesions in submandibular, pre and post
auricular lymph nodes.
In conclusion, carriers of the retinoblastoma gene have an
increased incidence for secondary tumors, which is augmented
by radiation therapy. Ophthalmologists should always keep
this in mind to be able to provide these patients with proper
counseling, plan for close long term follow up and update their
knowledge in the ﬁeld of retinoblastoma management.
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